BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10620058)

  • 1. Impaired development of bone mineral density during chemotherapy: a prospective analysis of 46 children newly diagnosed with cancer.
    Arikoski P; Komulainen J; Riikonen P; Parviainen M; Jurvelin JS; Voutilainen R; Kröger H
    J Bone Miner Res; 1999 Dec; 14(12):2002-9. PubMed ID: 10620058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in bone turnover and impaired development of bone mineral density in newly diagnosed children with cancer: a 1-year prospective study.
    Arikoski P; Komulainen J; Riikonen P; Voutilainen R; Knip M; Kröger H
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3174-81. PubMed ID: 10487683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density measured by dual-energy x-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs.
    Välimäki MJ; Tiihonen M; Laitinen K; Tähtelä R; Kärkkäinen M; Lamberg-Allardt C; Mäkelä P; Tunninen R
    J Bone Miner Res; 1994 May; 9(5):631-7. PubMed ID: 8053391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is bone turnover a determinant of bone mass in rheumatoid arthritis?
    Cortet B; Flipo RM; Pigny P; Duquesnoy B; Boersma A; Marchandise X; Delcambre B
    J Rheumatol; 1998 Dec; 25(12):2339-44. PubMed ID: 9858427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-level lifetime exposure to cadmium decreases skeletal mineralization and enhances bone loss in aged rats.
    Brzóska MM; Moniuszko-Jakoniuk J
    Bone; 2004 Nov; 35(5):1180-91. PubMed ID: 15542044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
    Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture: a retrospective and prospective population-based study of women.
    Akesson K; Ljunghall S; Jonsson B; Sernbo I; Johnell O; Gärdsell P; Obrant KJ
    J Bone Miner Res; 1995 Nov; 10(11):1823-9. PubMed ID: 8592961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of bone mass in renal hyperparathyroidism by newly developed bone metabolic markers: evaluation of serum levels of carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen and carboxy-terminal propeptide of type I procollagen.
    Katagiri M; Fukunaga M; Ohtawa T; Harada T
    World J Surg; 1996 Sep; 20(7):753-6; discussion 756-7. PubMed ID: 8678946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma.
    Abildgaard N; Brixen K; Eriksen EF; Kristensen JE; Nielsen JL; Heickendorff L
    Haematologica; 2004 May; 89(5):567-77. PubMed ID: 15136220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation with bone histomorphometry.
    Eriksen EF; Charles P; Melsen F; Mosekilde L; Risteli L; Risteli J
    J Bone Miner Res; 1993 Feb; 8(2):127-32. PubMed ID: 8442431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced bone mineral density at diagnosis and bone mineral recovery during treatment in children with Graves' disease.
    Lucidarme N; Ruiz JC; Czernichow P; Léger J
    J Pediatr; 2000 Jul; 137(1):56-62. PubMed ID: 10891822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
    Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
    J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical markers as predictors of rates of bone loss after menopause.
    Rogers A; Hannon RA; Eastell R
    J Bone Miner Res; 2000 Jul; 15(7):1398-404. PubMed ID: 10893690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL
    J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.